Suven Life Sciences (Suven) announces today that the grant of one product patent from Canada and one product patent from Sri Lanka corresponding to the New Chemical Entity for the treatment of disorders associated with Neurodegenerative diseases and patents are valid through 2034 and 2026 respectively.

The granted claims of the patents include the class of selective H3 and 5-HT6 compounds respectively and are being developed as therapeutic agents for neurodegenerative disorders such as Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia and sleep disorders like Narcolepsy etc.

''We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,'' says Venkat Jasti, CEO of Suven.

Shares of the company gained Rs 5.9, or 2.21%, to trade at Rs 272.35. The total volume of shares traded was 119,804 at the BSE (1.04 p.m., Tuesday).